Exagen (Exagen) Interest Expense : $-2.25 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Exagen's interest expense for the three months ended in Mar. 2024 was $ -0.55 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.25 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Exagen's Operating Income for the three months ended in Mar. 2024 was $ -3.00 Mil. Exagen's Interest Expense for the three months ended in Mar. 2024 was $ -0.55 Mil. Exagen did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Exagen Interest Expense Historical Data

The historical data trend for Exagen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Interest Expense Chart

Exagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3.49

-2.57

-2.63

-2.45

-2.34

Exagen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.64	-0.57	-0.56	-0.57	-0.55

Exagen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.25 Mil.

Exagen (NAS:XGN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Exagen's Interest Expense for the three months ended in Mar. 2024 was $-0.55 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-3.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $21.77 Mil.

Exagen's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Exagen did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Exagen (Exagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

E08A:Germany

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Executives

John Aballi	director, officer: President and CEO	C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p.	10 percent owner	11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi	officer: Chief Financial Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine	officer: Chief Operating Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson	director	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L	director, 10 percent owner	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker	director	441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes	director	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack	officer: Chief Medical Officer	C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux	officer: Chief Scientific Officer	C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081